Trial is needed of ACE inhibitors plus β blockers in survivors of myocardial infarctionBMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7160.751a (Published 12 September 1998) Cite this as: BMJ 1998;317:751
- Finlay A McAlister, Clinical scholar
- Divisions of General Internal Medicine and Clinical Epidemiology, Ottawa Civic Hospital, Ottawa, Canada K1Y 4E9
EDITOR—Mehta and Eagle have provided an overview of secondary prevention in survivors of myocardial infarction.1 As well as striving to increase the use of efficacious treatments in these patients, we must be aware of the potential for polypharmacy (and its effects on patient compliance and healthcare costs).
Clinical trials have established that aspirin, β blockers, statins, and angiotensin converting enzyme inhibitors are all associated with survival benefits when tested individually in survivors of myocardial infarction, but we need more information on the incremental benefits (and costs) when several (or all …